SE461616B - Foerfarande och testsats vid diagnos av iga nefropati med bestaemning av fibronektin-iga-komplex - Google Patents
Foerfarande och testsats vid diagnos av iga nefropati med bestaemning av fibronektin-iga-komplexInfo
- Publication number
- SE461616B SE461616B SE8701905A SE8701905A SE461616B SE 461616 B SE461616 B SE 461616B SE 8701905 A SE8701905 A SE 8701905A SE 8701905 A SE8701905 A SE 8701905A SE 461616 B SE461616 B SE 461616B
- Authority
- SE
- Sweden
- Prior art keywords
- iga
- fibronectin
- complex
- binding
- carrier
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- 238000003745 diagnosis Methods 0.000 title claims abstract description 12
- 102000016359 Fibronectins Human genes 0.000 claims abstract description 39
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 39
- 238000009739 binding Methods 0.000 claims abstract description 33
- 230000027455 binding Effects 0.000 claims abstract description 32
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims abstract description 13
- 206010021263 IgA nephropathy Diseases 0.000 claims abstract description 9
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 7
- 210000001124 body fluid Anatomy 0.000 claims abstract description 5
- 239000010839 body fluid Substances 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims abstract description 5
- 101150026046 iga gene Proteins 0.000 claims description 38
- 102000008186 Collagen Human genes 0.000 claims description 15
- 108010035532 Collagen Proteins 0.000 claims description 15
- 229920001436 collagen Polymers 0.000 claims description 15
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 13
- 229960002897 heparin Drugs 0.000 claims description 13
- 229920000669 heparin Polymers 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 7
- 108090001090 Lectins Proteins 0.000 claims description 6
- 102000004856 Lectins Human genes 0.000 claims description 6
- 239000002523 lectin Substances 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 5
- 108010073385 Fibrin Proteins 0.000 claims description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 229950003499 fibrin Drugs 0.000 claims description 5
- 229960005188 collagen Drugs 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 230000009830 antibody antigen interaction Effects 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 244000228957 Ferula foetida Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000000758 substrate Substances 0.000 abstract description 11
- 230000009870 specific binding Effects 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 102000012422 Collagen Type I Human genes 0.000 description 9
- 108010022452 Collagen Type I Proteins 0.000 description 9
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 108010084553 jacalin Proteins 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DAPUDVOJPZKTSI-UHFFFAOYSA-L ammonium nickel sulfate Chemical compound [NH4+].[NH4+].[Ni+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DAPUDVOJPZKTSI-UHFFFAOYSA-L 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Rehabilitation Therapy (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8701905A SE461616B (sv) | 1987-05-08 | 1987-05-08 | Foerfarande och testsats vid diagnos av iga nefropati med bestaemning av fibronektin-iga-komplex |
| US07/431,546 US5139932A (en) | 1987-05-08 | 1988-05-09 | Method and a kit for the diagnosis of iga nephropathy |
| EP88904694A EP0363397B1 (de) | 1987-05-08 | 1988-05-09 | Satz und verfahren zur diagnose der iga-nephropathie |
| PCT/SE1988/000240 WO1988008983A1 (en) | 1987-05-08 | 1988-05-09 | A METHOD AND A KIT FOR THE DIAGNOSIS OF IgA NEPHROPATHY |
| JP63504340A JP2592121B2 (ja) | 1987-05-08 | 1988-05-09 | ＩｇＡ腎臓病の診断のための方法及びキツト |
| AT88904694T ATE68600T1 (de) | 1987-05-08 | 1988-05-09 | Satz und verfahren zur diagnose der iganephropathie. |
| DE8888904694T DE3865678D1 (de) | 1987-05-08 | 1988-05-09 | Satz und verfahren zur diagnose der iga-nephropathie. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8701905A SE461616B (sv) | 1987-05-08 | 1987-05-08 | Foerfarande och testsats vid diagnos av iga nefropati med bestaemning av fibronektin-iga-komplex |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8701905D0 SE8701905D0 (sv) | 1987-05-08 |
| SE8701905L SE8701905L (sv) | 1988-11-09 |
| SE461616B true SE461616B (sv) | 1990-03-05 |
Family
ID=20368457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8701905A SE461616B (sv) | 1987-05-08 | 1987-05-08 | Foerfarande och testsats vid diagnos av iga nefropati med bestaemning av fibronektin-iga-komplex |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5139932A (de) |
| EP (1) | EP0363397B1 (de) |
| JP (1) | JP2592121B2 (de) |
| AT (1) | ATE68600T1 (de) |
| DE (1) | DE3865678D1 (de) |
| SE (1) | SE461616B (de) |
| WO (1) | WO1988008983A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04502363A (ja) * | 1988-12-12 | 1992-04-23 | バード ダイアグノスティック サイエンシズ，インコーポレイティド | 癌及びその他の疾病の診断としての基底膜成分の検出 |
| DE69221666T2 (de) * | 1991-05-24 | 1998-01-15 | Wakamoto Pharma Co Ltd | Verfahren zur Diagnose von Nierenkrankheiten durch Nachweisung von Albuminfragmenten |
| US20060281681A1 (en) | 1997-05-28 | 2006-12-14 | Pilon Aprile L | Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease |
| US6255281B1 (en) * | 1997-05-28 | 2001-07-03 | Claragen, Inc. And U.S. Government | Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| US7122344B2 (en) | 1997-05-28 | 2006-10-17 | Claragen, Inc. | Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| ATE396399T1 (de) * | 1998-03-31 | 2008-06-15 | Asahi Kasei Pharma Corp | Verfahren zur untersuchung der iga-nephropathie |
| WO2002006346A1 (en) * | 2000-07-19 | 2002-01-24 | Battelle Memorial Institute | ASSAY FOR IDENTIFYING υ2u-GLOBULIN-MEDIATED NEPHROPATHY |
| FI20010868A0 (fi) * | 2001-04-25 | 2001-04-25 | Markku Maeki | Menetelmä ja välineet gluteenin indusoimien tautien havaitsemiseksi |
| US20100015044A1 (en) * | 2005-08-03 | 2010-01-21 | Robert Qiu | Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases |
| EP2295966B1 (de) * | 2008-06-02 | 2013-01-02 | Eisai R&D Management Co., Ltd. | Iga-nephropathie-nachweisverfahren und nachweiskit |
| JPWO2009147999A1 (ja) * | 2008-06-02 | 2011-10-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ＩｇＡ腎症の検査方法及び検査キット |
| JP5677294B2 (ja) | 2009-06-10 | 2015-02-25 | 原 正則 | 腎疾患の検査方法 |
| US9339526B2 (en) | 2011-01-17 | 2016-05-17 | University Of Manitoba | Methods for treating disorders that involve immunoglobulin A |
| US9598733B2 (en) | 2011-02-17 | 2017-03-21 | The Trustees Of Columbia University In The City Of New York | Methods for identifying subjects with a genetic risk for developing IgA nephropathy |
| US10202647B2 (en) | 2013-04-12 | 2019-02-12 | The Trustees Of Columbia University In The City Of New York | Mutations in DSTYK cause dominant urinary tract malformations |
| JP7473398B2 (ja) | 2020-05-28 | 2024-04-23 | シスメックス株式会社 | キャリブレータ、複合体、及びＩｇＡ凝集体を測定する方法 |
| KR20250172593A (ko) * | 2023-04-26 | 2025-12-09 | 오리엔탈고우보고오교가부시끼가이샤 | IgA 신병증의 판정 방법 |
-
1987
- 1987-05-08 SE SE8701905A patent/SE461616B/sv not_active IP Right Cessation
-
1988
- 1988-05-09 DE DE8888904694T patent/DE3865678D1/de not_active Expired - Fee Related
- 1988-05-09 JP JP63504340A patent/JP2592121B2/ja not_active Expired - Lifetime
- 1988-05-09 WO PCT/SE1988/000240 patent/WO1988008983A1/en not_active Ceased
- 1988-05-09 EP EP88904694A patent/EP0363397B1/de not_active Expired - Lifetime
- 1988-05-09 US US07/431,546 patent/US5139932A/en not_active Expired - Fee Related
- 1988-05-09 AT AT88904694T patent/ATE68600T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH02503714A (ja) | 1990-11-01 |
| JP2592121B2 (ja) | 1997-03-19 |
| WO1988008983A1 (en) | 1988-11-17 |
| SE8701905D0 (sv) | 1987-05-08 |
| SE8701905L (sv) | 1988-11-09 |
| US5139932A (en) | 1992-08-18 |
| EP0363397B1 (de) | 1991-10-16 |
| ATE68600T1 (de) | 1991-11-15 |
| DE3865678D1 (de) | 1991-11-21 |
| EP0363397A1 (de) | 1990-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE461616B (sv) | Foerfarande och testsats vid diagnos av iga nefropati med bestaemning av fibronektin-iga-komplex | |
| Jefferis et al. | Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study | |
| Faaber et al. | Cross-reactivity of anti-DNA antibodies with proteoglycans | |
| EP0185870B1 (de) | Immunoassays für denaturierte Proteinanalyte, insbesondere HbAlC und monoklonale Antikörper dafür | |
| JPS60501179A (ja) | ヒトｔ細胞白血病ウイルスの検出方法及び検出用物品 | |
| Prakobphol et al. | Human low-molecular-weight salivary mucin expresses the sialyl lewisx determinant and has L-selectin ligand activity | |
| YANG et al. | Immunoblot analysis of a 10 kDa antigen in cyst fluid of Taenia solium metacestodes | |
| US5976810A (en) | Method of detecting autoantibody present in the serum of rheumatic | |
| CN112513288B (zh) | 细菌性阴道病诊断 | |
| KR100296198B1 (ko) | 시이엔피-비(cenp-b)에피토프 | |
| JPH06501924A (ja) | シトケラチン２０又はシトケラチン２０の蛋白質分解による切断によりえられたそのα―ラセン状中央部片の免疫学的同定法 | |
| Ebers et al. | Oligoclonal immunoglobulins in subacute sclerosing panencephalitis and multiple sclerosis: a study of idiotypic determinants | |
| EP0585960A2 (de) | Diagnostisches Verfahren für Autoimmunkrankenheiten | |
| Genco et al. | The immunoglobulins of equine colostrum and parotid fluid | |
| Wagh et al. | Human oviductal fluid proteins. V. Identification of human oviductin-I as alpha-fetoprotein | |
| Minden et al. | False positive radio-immunoautograph lines associated with immunoglobulins from normal sera | |
| Herrera-Esparza et al. | Posttranslational protein modification in the salivary glands of Sjögren’s syndrome patients | |
| Greenberg et al. | Nuclear localization of valosin‐containing protein in normal muscle and muscle affected by inclusion‐body myositis | |
| Faulk et al. | Characterization of rabbit fast and slow 6· 6S IgG | |
| Berg et al. | Demonstration of PDC‐E1 subunits as major antigens in the complement‐fixing fraction M4 and re‐evaluation of PDC‐E1‐specific antibodies in PBC patients | |
| Bassett et al. | STUDIES ON HUMAN ANTIBODIES: III. Amino Acid Composition of Four Antibodies from One Individual | |
| Spaeth et al. | An Extended Clq‐Binding Assay Using Lactoperoxidase‐and Chloramine‐T‐Iodinated Clq: Immediate Distinction between Immune‐Aggregate‐Mediated and Non‐Immune‐Aggregate‐Mediated Clq Binding | |
| JPH0249162A (ja) | がんの血清測定法 | |
| Moore et al. | Purification and use of the C3d subunit of C3 | |
| FI104219B (fi) | Diagnostinen menetelmä ja testaustarvikesarja multippeliskleroosin määrittämiseksi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8701905-5 Effective date: 19921204 Format of ref document f/p: F |